Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...
U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...
As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...
In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...
MedPage Today on MSN
FDA Probes RSV Drug Safety; Why Some Cancers Shouldn't Be Treated; New Mpox Strain
Health news and commentary gathered by MedPage Today staff ...
Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...
News-Medical.Net on MSN
RSV can have profound, long-lasting effects in hospitalized adults
Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children. But a new ...
FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...
Researchers evaluated the real-world effectiveness of nirsevimab in preventing ICU admission and acute respiratory failure associated with RSV among infants.
Dec 12 (Reuters) - GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory ...
Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...
Everyday Health on MSN
RSV Could Raise the Risk of Heart Attack and Stroke
In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback